Chronic Lymphocytic Leukemia

John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.

An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.

John Allan, MD, compares the available approved BTK inhibitors for treating chronic lymphocytic leukemia.

A leukemia specialist details the Resonate-2 clinical trial studying BTK inhibitor ibrutinib.

John Allan, MD, highlights treatment options in the first-line setting for chronic lymphocytic leukemia.

A key opinion leader shares insight into testing and risk stratification for chronic lymphocytic leukemia.

John Allan, MD, presents and reviews the case of a 67-year-old man with chronic lymphocytic leukemia.

The combination of low-dose acalabrutinib/rituximab showed to be feasible and effective in CLL/SLL.

Acalabrutinib demonstrated a favorable risk-benefit profile in R/R CLL.

Compared with ibrutinib, acalabrutinib demonstrates less toxicity burden In CLL.

Preliminary results from the phase 2 ERADIC trial signal promise for ibrutinib plus venetoclax for the treatment of chronic lymphocytic leukemia.

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline recommended treatment options for patients with chronic lymphocytic leukemia based on a case scenario, with questions by Targeted Oncology.

Increased rates of complete responses with bone marrow undetectable minimal residual disease were seen with the time-limited combination of ibrutinib plus chemoimmunotherapy in younger fit patients with chronic lymphocytic leukemia.

While no significant difference in overall survival benefit between the treatment groups was observed, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.

Compared to those who received rituximab and bendamustine, elderly patients treated with ibrutinib-containing regimens for chronic lymphocytic leukemia saw a progression-free survival benefit.

The costs of treatment and time spent managing adverse effects varied significantly in patients with chronic lymphocytic leukemia treated with acalabrutinib, ibrutinib, and venetoclax.

Jennifer R. Brown, MD, PhD, discusses the implications of the SEQUOIA trial, which looked at the combination of zanubrutinib and venetoclax for the treatment of patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.

Undetectable minimal residual disease may be achieved with time-limited ublituximab and umbralisib added to ibrutinib in patients with chronic lymphocytic leukemia.

Javier L. Munoz, MD, MBA, discussed best options and timing for treating chronic lymphocytic leukemia now and beyond the pandemic

Looking at frontline venetoclax based combinations shows promise for fit patients with CLL.

In an analysis of the phase 3 GLOW study, data showed promise for the use of ibrutinib/venetoclax in the frontline setting.

New results from the CAPTIVATE study demonstrated that treatment with ibrutinib and venetoclax in the first-line setting of patients with CLL continues to elicit durable responses to placebo.

Data from the phase 2 VISION trial showed that restarting treatment with the combination was feasible in a select group of patients who initially had undetectable MRD after 15 cycles of treatment.

BOVen was found to induce MRD and to have a tolerable safety profile.

The incidence of adverse events appeared to increase when bendamustine was added to venetoclax for the treatment of patients with released or refractory chronic lymphocytic leukemia